To test whether the combined targeting of PAFR and EGFR resulted in enhanced growth inhibition compared with the single inhibition, half of the IC50 for each drug was used to treat ovarian cancer cells, followed by the CCK-8 assay. The gene discussed is PTAFR; the disease is ovarian cancer.